Business Standard

Zydus receives USFDA's tentative approval for Levothyroxine Sodium for injection

Image

Capital Market

Zydus Lifesciences' U.S. subsidiary Zydus Pharmaceuticals (USA) Inc. has received tentative approval from the United States Food and Drug Administration (USFDA) to market Levothyroxine Sodium for injection, 100 mcg/vial, 200 mcg/vial, and 500 mcg/vial (USRLD: Levothyroxine Sodium injection manufactured by Fresenius Kabi USA, LLC).

Levothyroxine Sodium injection is indicated for the treatment of myxedema coma. Levothyroxine Sodium injection had annual sales of USD 45.2 mn in the United States according to IQVIA data (IQVIA MAT Sep 2022).

The drug will be manufactured at the group's injectable manufacturing facility at Jarod, near Vadodara, India.

Powered by Capital Market - Live News

 

Disclaimer: No Business Standard Journalist was involved in creation of this content

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: Nov 28 2022 | 9:05 AM IST

Explore News